Crossmark

Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings

Published Online: 2024-09-29

Published Print: 2024-12

Authors

Obara, Naoshi https://orcid.org/0000-0001-6563-3093
Hatanaka, Shigeki

Tsuji, Yukie

Higashi, Koji
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000047864 at UMIN Japan

Documents that mention this clinical trial

Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings
https://doi.org/10.1007/s12185-024-03847-4
Funding

Funding for this research was provided by:

Kyowa Kirin Co., Ltd.
License Information

Text and Data Mining valid from 2024-09-29

Version of Record valid from 2024-09-29
More Information

Article History

Received: 30 January 2024

Revised: 29 August 2024

Accepted: 6 September 2024

First Online: 29 September 2024

Declarations

:

: Naoshi Obara received research funding from Kyowa Kirin Co., Ltd., Alexion Pharmaceuticals, Inc., Novartis Pharma K.K., and Chugai Pharmaceutical Co., Ltd. outside the submitted work. Also, Naoshi Obara is an editor for International Journal of Hematology. Shigeki Hatanaka, Yukie Tsuji, and Koji Higashi are employees of Kyowa Kirin Co., Ltd., which funded this survey.

Document is current